Pluri Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Pluri Inc. (PLUR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $3.90 per share for the 6-month period ending 2016-12-31, per its 10-Q filed 2017-02-08.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2017-02-08
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2016-09-30 was $4.00.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2016 was $4.40, a 43.52% decline from fiscal 2015.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2015 was $7.79, a 32.79% decline from fiscal 2014.
- Pluri Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2014 was $11.59.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2016-12-31 | $3.90 10-Q · filed 2017-02-08 | |||
| 2016-09-30 | $4.00 10-Q · filed 2016-11-07 | |||
| 2016-06-30 | $4.40 10-K · filed 2016-09-07 | |||
| 2016-03-31 | $4.40 10-Q · filed 2016-05-09 | |||
| 2015-06-30 | $7.79 10-K · filed 2015-09-09 | |||
| 2015-03-31 | $4.40 10-Q · filed 2015-05-06 | |||
| 2014-06-30 | $11.59 10-K · filed 2014-09-11 | |||
| 2014-03-31 | $11.59 10-Q · filed 2014-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |